Cefotaxime sodium sterile API, CAS 64485-93-4, molecular formula C₁₆H₁₆N₅NaO₇S₂, molecular weight 477.45 g/mol, is a white to faintly yellow crystalline powder released under the current European Pharmacopoeia and United States Pharmacopeia monographs for cefotaxime sodium. The sterile grade differs from non-sterile cefotaxime sodium by the addition of sterility assurance, bacterial endotoxin control, and injectable particulate control, not by a separate CAS number or a different chemical entity. The vendor-specific model or grade suffix—commonly an ST or INJ identifier after the molecule name—must be verified against the certificate of analysis; no universal part number exists across API producers. The API is intended primarily for dry powder injectable formulations after reconstitution with water for injection or suitable diluents. Tablet, capsule, and granule applications are restricted by the oral bioavailability characteristics of the sodium salt; the molecule is not bioequivalent to an oral prodrug such as cefpodoxime proxetil.

Physical handling on a manufacturing line is controlled by residual water and powder flow. The parenteral grade is freely soluble in water; a 1 g vial reconstituted with 10 mL water for injection yields approximately 100 mg/mL cefotaxime sodium solution. The pH of a 10% solution is specified between 4.5 and 6.5. Because the dissolved molecule undergoes pH- and temperature-dependent hydrolysis, reconstituted solution is not intended for prolonged storage; in-use stability is established in the finished product license. The sterile API is shipped in double polyethylene bags inside a foil laminate to maintain water content below 3.0%.

Why does the sodium salt enter injectable monographs but not conventional tablet or capsule development screens?

The beta-lactam ring undergoes acid-catalyzed hydrolysis in gastric fluid, and the ionized carboxylate limits passive permeability across the intestinal epithelium. These two factors place cefotaxime sodium outside the normal development pathway for oral tablets and capsules, even though the powder can be compressed or filled in a dry state. Aqueous wet granulation at pH below 4 accelerates opening of the beta-lactam ring and generates microbiologically inactive degradation products. Direct compression and roll compaction are therefore the only solid oral processes that can be evaluated without immediately compromising chemical stability; capsule filling requires tight control of powder water activity and a desiccant-based packaging system.

For oral granules, the API can be layered onto sugar spheres or granulated with non-hygroscopic binders, but the resulting dosage form remains a non-systemic or locally active delivery prospect unless a permeation enhancer or enteric prodrug approach is incorporated. Published data for direct oral cefotaxime sodium absorption in humans is limited. A manufacturer seeking an oral third-generation cephalosporin should compare cefpodoxime proxetil or cefixime rather than cefotaxime sodium. If a proprietary oral formulation is developed, the dissolution method must be validated by HPLC because no compendial oral monograph for cefotaxime sodium exists; this contrasts with injectable standards, where reconstitution clarity and monograph identification methods provide a defined release base.

Chemical stability of beta-lactam sodium salts follows pseudo-first-order hydrolysis in aqueous solution; the rate constant increases as pH falls below 4 and as temperature rises. Lyophilized or dry powder formulations are far more stable than solutions, but dry-state degradation still occurs if the amorphous fraction is elevated or if the powder is exposed to humid air. The sterile API is therefore dried to a crystalline state with controlled residual water rather than a lyophilized amorphous cake. During tablet compression, shear-induced heating is usually less significant than moisture-induced degradation; however, compressing at high dwell time on a rotary press can generate enough local temperature increase to initiate localized beta-lactam degradation if water is present above the monograph limit. Formulators must therefore evaluate tablet compression force, turret speed, and granule water activity as linked variables rather than as independent settings.

Sterile API release limits and compendial test designations

The endotoxin limit is derived from the dose-based formula in USP <85> rather than a fixed API property. For a 2 g parenteral dose administered over 1 h in a 70 kg patient, the calculated limit is approximately 0.175 EU/mg; many pharmacopoeial monographs set the limit at 0.20 EU/mg to provide operational margin while remaining below the calculated value. This limit must be recalculated if the finished product is intended for intrathecal use, where the K value is lower. Particulate matter limits for the reconstituted injection follow the small-volume parenteral container criteria of USP <788>: not more than 6000 particles ≥10 µm and not more than 600 particles ≥25 µm per container, unless the licensed product monograph specifies otherwise.

When the desacetyl metabolite and protein binding profile are compared with ceftriaxone sodium

Cefotaxime sodium is structurally and pharmacokinetically distinct from ceftriaxone sodium, although both are classified as parenteral third-generation cephalosporins. The protein binding of cefotaxime is approximately 40%, whereas ceftriaxone binding is reported at 85–95%. Higher ceftriaxone binding supports once-daily dosing but also creates potential for protein-binding displacement interactions with other highly bound drugs. Cefotaxime is partially metabolized to desacetylcefotaxime, which retains antimicrobial activity and is eliminated renally; ceftriaxone has no major active metabolite. The desacetyl metabolite prolongs effective activity beyond the short parent half-life of 0.8–1.5 h and modifies the dependence of elimination on hepatic clearance. Ceftriaxone half-life is 5.8–8.7 h, allowing less frequent administration but also leading to higher biliary concentrations and the well-documented calcium-ceftriaxone precipitation risk in neonatal parenteral mixtures. Cefotaxime sodium lacks the N-methylthiotetrazole side chain associated with older cephalosporins such as cefamandole and cefoperazone; this difference reduces the expected risk of disulfiram-like reactions and hypoprothrombinemia. These pharmacokinetic and structural boundaries translate directly into different IV compounding schedules and different safety monitoring obligations on the fill line.

Cefpodoxime proxetil is the oral-prodrug comparator for tablet, capsule, and granule development. Cefotaxime sodium is not interchangeable with cefpodoxime proxetil on an equal-weight basis because the active moiety content and absorption kinetics differ. Dose conversion requires cefpodoxime activity rather than cefotaxime sodium mass. Against Pseudomonas aeruginosa, ceftazidime and cefepime are generally more potent than cefotaxime; this is relevant only for injectable therapy and does not imply interchangeability on a hospital formulary. Against methicillin-resistant staphylococci, Enterococcus faecium, and anaerobic Bacteroides fragilis groups, cefotaxime sodium is not reliably active; formulation of an oral or injectable product does not alter that microbiological boundary. Susceptibility testing must follow CLSI M100 or EUCAST breakpoints; a compendial API release test does not establish clinical efficacy against any specific isolate.

Residual moisture, aseptic crystallization, and dry powder filling throughput

Sterile cefotaxime sodium is produced by aseptic crystallization and low-temperature vacuum drying rather than terminal steam sterilization because the beta-lactam ring degrades at autoclave temperatures. Aseptic processing is performed under EU GMP Annex 1 Grade A conditions, with background classified as ISO 14644-1 Class 5 at rest. Terminal sterilization of the sealed vial is generally unsuitable; if attempted, degradation products increase and assay falls below the anhydrous limit of 916 µg/mg. The sterile API is usually milled or sieved to a controlled particle size distribution before filling; the target D90 is batch-specific and must be described in the drug master file. Powder flow through an auger or vacuum dosing wheel is sensitive to residual water. At water content values above 3.0%, caking in the hopper and bridging in the dosing chamber can raise fill weight RSD above ±5% on a 10–30 vials/min aseptic line. In-process weight checks and 100% vial weight verification are used to segregate underfilled units; no reliance is placed on average fill weight alone.

Residual solvent control is tied to the crystallization solvent system. If acetone is used as the final solvent, its ICH Q3C Class 3 limit of 5000 ppm applies; methanol, if used, is Class 2 and limited to 3000 ppm. Current Ph. Eur. and USP residual solvent chapters require that these limits be met before release for pharmaceutical use. In an oral tablet or capsule granulation suite, the sterile API enters an environment governed by nonsterile microbial limits such as USP <61> and USP <62> unless the entire downstream unit operation is validated as aseptic. Consequently, the sterile attribute is not preserved through ordinary tableting.

Recommended storage is below 25°C in a dry environment, protected from light. The double polyethylene bag is placed inside a heat-sealed aluminum laminate pouch; desiccant is added when the supplier can demonstrate moisture ingress below 3.0% water content throughout the retest period. The retest period is assigned from stability data generated under ICH Q1A conditions. Batch-to-batch variability in specific surface area can shift reconstitution time even when all release tests pass; a practical reconstitution time test in the finished product specification is therefore used to detect surface-area drift.

Cleaning validation for cefotaxime sodium uses swab and rinse sampling with an HPLC limit based on a toxicologically derived permitted daily exposure. Because the molecule is a beta-lactam, cross-contamination into non-beta-lactam product lines carries sensitization risk; dedicated or campaign manufacturing is common. The sterile API must be dispensed in a negative-pressure weigh booth with local exhaust to control powder aerosol. Operators handling the powder are protected by current occupational exposure bands; the material is a potential sensitizer by inhalation and skin contact.

Formulation-specific compatibility data for cefotaxime sodium in tablet, capsule, or granule dosage forms are scarce in public pharmacopoeial monographs. Excipient compatibility studies must quantify assay loss and total degradation products under stressed conditions, typically 40°C/75% RH for 4 weeks, using a stability-indicating HPLC method. Acidic fillers such as citric acid, hygroscopic binders such as povidone at high humidity, and unbuffered aqueous granulation media should be considered incompatible with the beta-lactam carboxylate unless water activity is maintained below a pre-validated threshold. Direct compression with microcrystalline cellulose and a dry binder is a lower-risk starting point for any non-invasive oral feasibility study. The absence of an oral compendial monograph means that release testing must be justified case-by-case with validated methods; no official dissolution apparatus or acceptance criterion exists for this specific configuration. Published data for this specific configuration is limited, and the sodium salt remains an injectable API unless the pharmaceutical development package establishes oral absorption through a proprietary enabling system.